Table 4.

Correlation between the increasing AFP cut-offs and the baseline clinical variables.

	AFP Cut-Offs
	20 ng/mL			200 ng/mL			400 ng/mL			1000 ng/mL
Parameter	<	≥	p 2	<	≥	p 2	<	≥	p 2	<	≥	p 2
Sex (F), %	30	32	0.368	31	39	0.102	30	50	0.045	31	47	0.020
Age at HCC enrollment, years, median	73	72	0.672	73	72	0.753	73	72	0.903	73	73	0.669
Viral etiology, %	76	87	0.073	79	89	0.242	79	91	0.201	79	87	0.743
Diameter ≥ 5 cm, %	11	24	0.006	14	30	0.027	15	29	0.032	15	33	0.045
Child-Pugh score A, %	82	79	0.566	83	63	0.061	82	62	0.022	83	53	0.012
BCLC A, %	75	81	0.354	76	89	0.153	77	86	0.426	77	87	0.532
HCC Grade 1 1–2, %	84	69	<0.001	88	52	<0.001	87	53	<0.001	88	36	<0.001
PVT, %	13	20	0.178	16	19	0.612	15	19	0.670	16	20	0.713
Malignant PVT, %	12	18	0.192	14	11	0.713	14	9	0.748	14	13	0.947

¹ Available for 237 patients; ² Mann–Whitney analysis or Fisher’s exact test; AFP: alpha-fetoprotein; BCLC: Barcellona Clinic Liver Cancer; HCC: hepatocellular carcinoma; PVT: portal vein thrombosis.